Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $25 | $34 | $20 |
| G&A Expenses | $8 | $7 | $7 | $7 |
| SG&A Expenses | $8 | $7 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $27 | $0 | $0 | $0 |
| Operating Expenses | $41 | $32 | $42 | $27 |
| Operating Income | -$41 | -$32 | -$42 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $5 | $5 | $6 |
| Pre-Tax Income | -$36 | -$27 | -$37 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | -$27 | -$37 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.67 | -0.5 | -0.68 | -0.38 |
| % Growth | -34% | 26.5% | -78.9% | – |
| EPS Diluted | -0.67 | -0.5 | -0.68 | -0.38 |
| Weighted Avg Shares Out | 55 | 55 | 54 | 54 |
| Weighted Avg Shares Out Dil | 55 | 55 | 54 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $5 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$36 | -$32 | -$42 | -$27 |
| % Margin | – | – | – | – |